Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcela F Pasetti

Showing results (121-130 of 172) with videos related to

Pageof 18
Sort By:
Vaccine|December 20, 2018
A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunizationDavid I Bernstein, Marcela F Pasetti, Rebecca Brady, et al.
Infection and Immunity|July 26, 2021
Immunogenicity and Efficacy of Live-Attenuated <i>Salmonella</i> Typhimurium Vaccine Candidate CVD 1926 in a Rhesus Macaque Model of GastroenteritisEllen E Higginson, Aruna Panda, Franklin R Toapanta, et al.
Biologicals : Journal of the International Association of Biological Standardization|September 12, 2018
Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgGSjoerd Rijpkema, Jason Hockley, Alastair Logan, et al.
Science Translational Medicine|March 5, 2025
An oral norovirus vaccine tablet was safe and elicited mucosal immunity in older adults in a phase 1b clinical trialBecca A Flitter, Susan N Greco, Colin A Lester, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 10, 2020
Overcoming Waning Immunity in Pertussis Vaccines: Workshop of the National Institute of Allergy and Infectious DiseasesF Heath Damron, Mariette Barbier, Purnima Dubey, et al.
Clinical and Vaccine Immunology : CVI|October 7, 2016
Safety and Immunogenicity of a Parenterally Administered, Structure-Based Rationally Modified Recombinant Staphylococcal Enterotoxin B Protein Vaccine, STEBVaxWilbur H Chen, Marcela F Pasetti, Rajan P Adhikari, et al.
Frontiers in Immunology|April 24, 2023
H3N2 influenza hemagglutination inhibition method qualification with data driven statistical methods for human clinical trialsSheetal Sawant, Sarah Anne Gurley, R Glenn Overman, et al.
Infection and Immunity|September 26, 2018
Improved Tolerability of a Salmonella enterica Serovar Typhimurium Live-Attenuated Vaccine Strain Achieved by Balancing Inflammatory Potential with ImmunogenicityEllen E Higginson, Girish Ramachandran, Aruna Panda, et al.
The Journal of Infectious Diseases|October 29, 2010
Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissuesSamer S El-Kamary, Marcela F Pasetti, Paul M Mendelman, et al.
The Journal of Infectious Diseases|April 18, 2026
First-in-Human Evaluation of the Safety, Genetic Stability, and Immunogenicity of an Attenuated Shigella flexneri 2a Live Vector Expressing Enterotoxigenic Escherichia coli Antigens, Vaccine Strain CVD 1208S-122Wilbur H Chen, Eileen M Barry, Franklin R Toapanta, et al.
Pageof 18

Showing results (121-130 of 172) with videos related to

Sort By:
Pageof 18
Vaccine|December 20, 2018
A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunizationDavid I Bernstein, Marcela F Pasetti, Rebecca Brady, et al.
Infection and Immunity|July 26, 2021
Immunogenicity and Efficacy of Live-Attenuated <i>Salmonella</i> Typhimurium Vaccine Candidate CVD 1926 in a Rhesus Macaque Model of GastroenteritisEllen E Higginson, Aruna Panda, Franklin R Toapanta, et al.
Biologicals : Journal of the International Association of Biological Standardization|September 12, 2018
Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgGSjoerd Rijpkema, Jason Hockley, Alastair Logan, et al.
Science Translational Medicine|March 5, 2025
An oral norovirus vaccine tablet was safe and elicited mucosal immunity in older adults in a phase 1b clinical trialBecca A Flitter, Susan N Greco, Colin A Lester, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 10, 2020
Overcoming Waning Immunity in Pertussis Vaccines: Workshop of the National Institute of Allergy and Infectious DiseasesF Heath Damron, Mariette Barbier, Purnima Dubey, et al.
Clinical and Vaccine Immunology : CVI|October 7, 2016
Safety and Immunogenicity of a Parenterally Administered, Structure-Based Rationally Modified Recombinant Staphylococcal Enterotoxin B Protein Vaccine, STEBVaxWilbur H Chen, Marcela F Pasetti, Rajan P Adhikari, et al.
Frontiers in Immunology|April 24, 2023
H3N2 influenza hemagglutination inhibition method qualification with data driven statistical methods for human clinical trialsSheetal Sawant, Sarah Anne Gurley, R Glenn Overman, et al.
Infection and Immunity|September 26, 2018
Improved Tolerability of a Salmonella enterica Serovar Typhimurium Live-Attenuated Vaccine Strain Achieved by Balancing Inflammatory Potential with ImmunogenicityEllen E Higginson, Girish Ramachandran, Aruna Panda, et al.
The Journal of Infectious Diseases|October 29, 2010
Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissuesSamer S El-Kamary, Marcela F Pasetti, Paul M Mendelman, et al.
The Journal of Infectious Diseases|April 18, 2026
First-in-Human Evaluation of the Safety, Genetic Stability, and Immunogenicity of an Attenuated Shigella flexneri 2a Live Vector Expressing Enterotoxigenic Escherichia coli Antigens, Vaccine Strain CVD 1208S-122Wilbur H Chen, Eileen M Barry, Franklin R Toapanta, et al.
Pageof 18